Novartis AG (NVS)
97.37
+2.25
(+2.37%)
USD |
NYSE |
Apr 23, 13:35
Novartis Cash from Financing (TTM): -14.28B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -14.28B |
September 30, 2023 | -17.66B |
June 30, 2023 | -21.57B |
March 31, 2023 | -20.24B |
December 31, 2022 | -20.56B |
September 30, 2022 | -19.82B |
June 30, 2022 | -16.62B |
March 31, 2022 | -17.25B |
December 31, 2021 | -16.26B |
September 30, 2021 | -15.95B |
June 30, 2021 | -12.52B |
March 31, 2021 | -11.76B |
December 31, 2020 | -2.208B |
September 30, 2020 | -475.00M |
June 30, 2020 | -5.088B |
March 31, 2020 | -2.931B |
December 31, 2019 | -13.63B |
September 30, 2019 | -11.97B |
June 30, 2019 | -10.88B |
March 31, 2019 | -12.38B |
December 31, 2018 | -4.244B |
September 30, 2018 | -7.093B |
June 30, 2018 | -7.409B |
March 31, 2018 | -8.891B |
December 31, 2017 | -7.733B |
Date | Value |
---|---|
September 30, 2017 | -7.64B |
June 30, 2017 | -6.045B |
March 31, 2017 | -4.675B |
December 31, 2016 | -5.314B |
September 30, 2016 | -5.786B |
June 30, 2016 | -7.64B |
March 31, 2016 | -8.448B |
December 31, 2015 | -9.176B |
September 30, 2015 | -7.143B |
June 30, 2015 | -6.027B |
March 31, 2015 | -6.215B |
December 31, 2014 | -8.147B |
September 30, 2014 | -8.923B |
June 30, 2014 | -9.235B |
March 31, 2014 | -9.116B |
December 31, 2013 | -8.769B |
September 30, 2013 | -8.395B |
June 30, 2013 | -9.12B |
March 31, 2013 | -8.273B |
December 31, 2012 | -6.675B |
September 30, 2012 | -9.751B |
June 30, 2012 | -11.39B |
March 31, 2012 | -16.28B |
December 31, 2011 | -15.02B |
September 30, 2011 | -14.86B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-21.57B
Minimum
Jun 2023
-475.00M
Maximum
Sep 2020
-13.25B
Average
-14.28B
Median
Dec 2023
Cash from Financing (TTM) Benchmarks
Sandoz Group AG | -- |
Roche Holding AG | -4.652B |
Amgen Inc | 21.05B |
Incyte Corp | -20.03M |
MorphoSys AG | -- |